Business Context and Reporting Period
This Form 8-K is a current report filed by Obalon Therapeutics, Inc. (trading symbol: OBLN) on July 2, 2020, regarding events occurring on June 30, 2020. The registrant is a Delaware corporation and an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
On June 30, 2020, David Moatazedi resigned effective immediately from the following positions:
- Member of the Board of Directors
- Member of the Compensation Committee
- Member of the Audit Committee
The Company stated that the resignation was not due to any disagreement with the Board or the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the disclosure of the director's departure.
Key Facts for Investor Verification
- Confirm the effective date of David Moatazedi's resignation (June 30, 2020).
- Verify the composition of the Board of Directors following the resignation.
- Check for any subsequent filings regarding the appointment of a replacement director.